Trials / Completed
CompletedNCT00347217
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event
An Observational Study Into the Usage and Efficacy of Crestor 5mg as a Start Dosage in Achieving the LDL-C Target Level in Both Statin-naive and Treated Primary and Secondary Prevention Patients With a High Risk of a Cardiovascular Event.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,840 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin naïve and statin treated primary and secondary prevention patients at high risk for a cardiovascular event.
Conditions
Timeline
- Start date
- 2006-02-01
- Completion
- 2009-01-01
- First posted
- 2006-07-04
- Last updated
- 2011-08-30
Locations
215 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00347217. Inclusion in this directory is not an endorsement.